Author(s):
Azevedo-Silva, João ; Amorim, Manuela ; Tavares-Valente, Diana ; Sousa, Pedro ; Mohamath, Randolph ; Voigt, Emily A. ; Guderian, Jeffrey A. ; Kinsey, Robert ; Viana, Sofia ; Reis, Flávio ; Pintado, Manuela E. ; Paddon, Christopher J. ; Fox, Christopher B. ; Fernandes, João C.
Date: 2024
Persistent ID: http://hdl.handle.net/10400.14/47070
Origin: Veritati - Repositório Institucional da Universidade Católica Portuguesa
Subject(s): Glucans; Adjuvants; Aluminium salts; Squalene; SARS-CoV-2; Saccharomyces cerevisiae
Description
Vaccine adjuvants are important for enhancing vaccine efficacy, and although aluminium salts (Alum) are the most used, their limited ability to induce specific immune responses has spurred the search for new adjuvants. However, many adjuvants fail during product development due to manufacturability, supply, stability, or safety concerns. This work hypothesizes that protein-free yeast glucans can be used as vaccine adjuvants due to their known immunostimulatory activity and high abundancy. Thus, high molecular weight glucans with over 99% purity, comprising 64–70% β-glucans and 29–35% α-glucans, were extracted from a wild-type yeast and an engineered yeast to produce a steviol glycoside. These glucans underwent carboxymethylation to enhance solubility. Both water-dispersible and particulate glucans were evaluated as adjuvants, either alone or in combination with Alum or squalene stable emulsion (SE), for a SARS-CoV-2 vaccine. The study demonstrated that glucans triggered a robust immune response and enhanced the effects of Alum and SE when used in combination, both in vitro and in vivo. Water-dispersible glucans combined with Alum, and particulate glucans combined with SE, increased the production of specific antibodies against SARS-CoV-2 spike protein and enhanced serum neutralization titers against SARS-CoV-2 pseudovirus. Furthermore, the results indicated that larger molecular weight glucans from engineered yeast exhibited stronger immunogenic activity in comparison to wild-type yeast glucans. In conclusion, appropriately formulated glucans have the potential to be scalable, low-cost vaccine adjuvants, potentially overcoming the limitations of current adjuvants.
